ArticleBMJ open quality2025
Deprescribing vitamin B6 in a Singapore community hospital.
Article in BMJ open quality, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionVitamin B6 is commonly prescribed in hospitals in Singapore, although the clinical benefits are unclear. The Singapore Health Science Authority released a safety alert on high-dose vitamin B6 and the risk of peripheral neuropathy in May 2023.
methodsPatient case notes were reviewed at the beginning of the project, revealing that vitamin B6 was successfully deprescribed in 15.2% of eligible patients at our hospital.We used a swimlane diagram to map processes and cause-and-effect diagrams to identify root causes. We brainstormed for interventions using 72 change concepts, aiming to streamline medication management practices for deprescribing vitamin B6.
resultsThe percentage of patients with successfully deprescribed vitamin B6 increased from 15.2% to 100% during the project period. This corresponded to an 84.8% improvement. The additional 22 patients who had vitamin B6 deprescribed amounted to cost-savings of 1686 Singapore Dollars (SGD) per year. The projected savings over 1 year based on the current rate of deprescribing can be estimated to be SGD 13 567 per year. Furthermore, the new protocol that helped identify suitable patients for deprescribing has also led to positive feedback from the medical and pharmacy teams.
conclusionIn conclusion, this project facilitated a significant increase in the percentage of patients with successful vitamin B6 deprescription, reducing patients' pill burden, side effects and medication costs. It also resulted in a new protocol guideline for our healthcare teams to consider vitamin B6 deprescription in suitable patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.